Home › Fuchs' Endothelial Dystrophy › NCT05275972
Descemet Endothelial Thickness Comparison Trial II
RecruitingPhase 3
Descemet Endothelial Thickness Comparison Trials (DETECT I & II)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm * Peripheral endothelial cell count \>1000 cells/mm2 in at least one quadrant * Good surgical candidate for either procedure as determined by the surgeon * Willingness to participate * Age greater than 18 years Exclusion Criteria: * Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK * Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment * Other primary endothelial dysfunction such as PPMD * Visually significant optic nerve or macular pathology * Hypotony (Intraocular pressure \<10mmHg) * Any prior intraocular surgery other than cataract surgery * \>3 clock hours of ANY anterior or posterior synechiae * \>1 quadrant of stromal corneal vascularization * Inability to comply with post-operative instructions (i.e. unable to position) * Pregnancy
About the study
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
What is being tested
- Ripasudil (drug)
- Placebo (drug)
Sponsor: Stanford University · Participants: 60 · Started: Jan 23, 2023
Contact the study team
- Nicole Varnado, MPH · Phone: 650-725-1688
Official record on ClinicalTrials.gov — NCT05275972
Locations in the U.S.
| California | Stanford University, Palo Alto University of California Davis, Sacramento |
| Florida | University of Miami, Palm Beach Gardens |
| New Hampshire | Dartmouth-Hitchcock Medical Center, Lebanon |
| Oregon | Legacy Devers Eye Institute, Portland Oregon Health & Science University, Portland |
| Pennsylvania | University of Pennsylvania, Philadelphia Wills Eye Hospital, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.